COVID-19 Increases MS Relapses: What You Should Know

Credibility

Interest

Key Takeaway

Getting COVID-19 may lead to more frequent MS relapses for patients.

What They Found

This study looked at how COVID-19 affects people with multiple sclerosis (MS) over a period of about 1.7 years. They found that people who got COVID-19 had more relapses, which means their MS symptoms got worse more often. For instance, the rate of relapses in COVID-19 patients was 0.10 compared to 0.07 in those who didn't get it, like how someone might trip more often on a rough path than on a smooth one. They also noticed that COVID-19 shortened the time it took for patients to have their first relapse after the infection. However, the study showed that COVID-19 didn't seem to speed up long-term disability over this short time frame.

Who Should Care and Why

MS patients should care about these findings because it suggests that catching COVID-19 can make their condition worse and cause more frequent flare-ups. This is similar to how a cold might make someone feel more tired or sick, but for MS, it could lead to more serious symptoms. Caregivers also need to know this so they can help protect their loved ones from COVID-19 and be more vigilant about monitoring symptoms. Healthcare providers can use this information to guide their patients in managing risks and making informed choices about vaccinations and health practices. Overall, understanding these risks can help everyone involved take steps to keep MS patients healthier and more stable.

Important Considerations

The study looked at a large number of patients, but it only covered a specific time frame and may not show long-term effects. Also, the impacts of different treatments on COVID-19's effects were not fully explored. This means that while we know COVID-19 can worsen MS relapses, we still need more research to understand everything completely.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Progression Living with MS Specific Symptoms

Article Topics:

COVID-19disease progressionmultiple sclerosisrelapse

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Therapeutic advances in neurological disorders often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News